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intention (5 with recurrent lung cancer, and 2 with metastasis from lung 
cancer). Platinum ﬁducials and intravascular embolisation coils were 
used as markers. In total, 180 markers were placed: 67 intrapulmonal 
in 26 patients (median: 3 markers per tumor), 84 intravascular in 28 
patients (median: 3 makers per tumor), 25 extrapulmonal in 5 patients 
(median: 5 makers per tumor), and 4 markers in 1 patient with the 
bronchoscopic method. Seven days after marker placement, a planning 
CTscan was made and the GTV was contoured on a 4-D CT scan. The 
PTV equaled the GTV plus 5 mm. For early stage lung cancer, a total 
dose of 36 to 60 Gy, (median dose: 60 Gy) was given in 3 fractions. 
Solitary metastasis to the lung were treated with a total dose of 45 to 60 
Gy (median dose: 45 Gy) in 3 to 5 fractions. For palliative treatment, a 
total dose of 30 to 49 Gy was given in 3-7 fractions (median dose: 40 
Gy). The dose to the PTV was prescribed to the 70-85% isodose line. 
The response was evaluated according to the RECIST criteria with a 
CT scan 6-8 weeks after the last treatment and routinely thereafter. The 
median follow up with CTscan was 6 months (range: 2-18).
Results: Six patients (11%) had a pneumothorax after intrapulmonal 
placement. One patient had no symptoms. A thorax drain was placed 
in the 5 other patients. One patient complained of severe intrathora-
cal pain several hours after intravascular coil placement and 5 patients 
complained of haemoptoe, one after the intravascular coil placement 
and 4 after the intrapulmonal placement.
The local control was 97%. Seven tumors had a complete response, 
38 tumors had a partial response, 13 tumors had stable disease and 2 
tumors (both early stage lung cancer) were progressive, one after 8 
months and the other after 15 months. 
Conclusion: Low toxicity of marker placement was seen due to the 
4 methods. CyberKnife tumor tracking with markers is feasible and 
resulted in excellent tumor response.
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Background: Local recurrence is a major problem after (chemo-)ra-
diation for NSCLC. We hypothesized that for each individual patient 
the highest therapeutic ratio could be achieved by increasing the total 
tumor dose (TTD) to the limits of the normal tissues, delivered within 
5 weeks. In a theoretical model this resulted in an increase in tumor 
control probability from approximately 5% for a classical scheme (60 
Gy in 6 weeks) to 25% for the study scheme. Here, we report the ﬁrst 
results of a prospective clinical trial.
Methods: Twenty-nine patients with medically inoperable (stage I, 
n=2) or locally advanced NSCLC (stage III, n=27), in a good general 
condition (WHO-PS 0-1) and with a reasonable lung function (FEV1 
>50% of predicted) were included. Most patients (25/29) received 
induction chemotherapy. All patients were irradiated using an individu-
alized prescribed TTD, based on normal tissue constraints (mean lung 
dose 19 Gy, maximal spinal cord dose 54 Gy, no constraints for esopha-
gus) up to a maximal TTD of 79.2 Gy. Radiotherapy was delivered in 
1.8 Gy fractions, twice daily. Acute and late (>3 months) toxicity was 
scored using the CTCAE-criteria. A FDG-PET-CT scan (n=27) was 
performed to evaluate (metabolic) response 70 days after radiotherapy 
according to EORTC-criteria (PET) and RECIST-criteria (CT). The 
Kaplan-Meier method was used to compute overall survival. 
Results: The mean delivered dose was 62.7 Gy (range 46.8-79.2 Gy). 
This corresponds to a mean biological equivalent dose of approxi-
mately 80 Gy (2 Gy fractions, once daily, in 8 weeks). Most patients 
experienced mild acute toxicity, while only 2 patients (6.8%) developed 
acute grade 3 toxicity (n=1 dysphagia, n=1 cough) as depicted in ﬁgure 
1. Concerning late toxicity, 93% of patients (n=25) showed radiograph-
ic changes (75% in <25% and 18% in >25% of the lungs), while 12 out 
of 28 patients (43%) had clinical symptoms (>gr 1 pneumonitis). One 
patient (3.4%) died 51 days after radiotherapy due pneumonitis (treat-
ment related mortality). 
The post-radiotherapy PET-CT showed in 18 patients a metabolic 
response (41% complete metabolic response, 26% partial metabolic 
response), whereas only in 9 patients (33.3%) a response was seen 
on CT (p=0.01). Eight patients (29.6%) showed progressive disease, 
consisting of loco-regional progression (n=4), metastases (n=3) or a 
combination of both (n=1). With a mean FU of 13 months the mean 
overall survival was 16.7 months and a 1-yr survival of 65%.
Conclusions: Personalized HI-CHART radiation prescription based on 
normal tissue constraints is tolerable and initial results are promising.
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